Myositis disease
Therapeutic area
Neuromuscular Disease
Rare disease
No
- Definition
- An inflammatory disease involving a pathogenic inflammatory response in the muscle tissue.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Myositis disease
- Therapeutic area
- Neuromuscular Disease
- myositis disease
- inflammation of muscle tissue
- inflammatory disorder of muscle (disorder)
- muscle tissue inflammation
- Disease mechanisms
- Inflammatory
Sources for recorded values
- Severity
- Severe
- Neuromuscular Disease
- Rheumatology
Sources for recorded values
- MONDO ID
- MONDO:0021167
- Parent condition
- MONDO:0005336
Related records
Broader conditions (9)
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Human disease
- Inflammatory disease
- Muscle tissue disorder
- Musculoskeletal system disorder
- Myopathy
- Skeletal muscle disorder
Narrower conditions (56)
- Achilles bursitis
- Acquired idiopathic inflammatory myopathy
- Adermatopathic dermatomyositis
- Adult dermatomyositis
- Amyopathic dermatomyositis
- Anti-MDA5 dermatomyositis
- Anti-Mi2 dermatomyositis
- Anti-NXP2 dermatomyositis
- Anti-SAE dermatomyositis
- Anti-TIF1 dermatomyositis
- Antisynthetase syndrome
- Bacterial myositis
- Bicipital tenosynovitis
- Calcific tendinitis
- Childhood-onset autosomal recessive myopathy with external ophthalmoplegia
- Classical dermatomyositis
- Clinically amyopathic dermatomyositis
- Dermatomyositis
- Eosinophilic fasciitis
- Familial idiopathic inflammatory myopathy
Trials (221)
- A Case-control Study to Assess Risk of Coronary Heart Disease in Idiopathic Inflammatory Myopathy
- A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
- A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
- A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
- A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
- A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases
- A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease
- A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)
- A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis
- A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
- A Study of AZD0120 in Autoimmune Diseases
- A Study of BEN301 Injection in theTreatment of Autoimmune Diseases
- A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
- A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
- A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
- A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
- A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Drugs in development (21)
- Aldesleukin Phase 2
- Antilymphocyte immunoglobulin (horse) Phase 1
- Baricitinib Phase 2
- Belimumab Phase 2
- Celecoxib Phase 1
- Cyclophosphamide Phase 1
- Cyclosporine Phase 2
- Dantrolene Phase 2
- Dazukibart Phase 3
- Empasiprubart Phase 2
- FAPI GA-68 Early phase 1
- Infliximab Phase 2
- Nipocalimab Phase 2
- Omega-3-acid ethyl esters Phase 2
- Plamotamab Phase 1
- Prednisone Phase 2
- Rapcabtagene autoleucel Phase 2
- Rituximab Phase 2
- Sodium thiosulfate Phase 2
- Telitacicept Phase 2
Other linked drugs (1)
- Corticotropin